At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 6 enrolled
Drug / intervention
TAK-954 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, 3-Period, Incomplete Block Design Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAK-954 in Healthy Adult Participants
In Brief
A Phase 1 clinical trial evaluating TAK-954 and TAK-954 Placebo for Healthy Volunteers. Completed, enrolled 6 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety, tolerability, and PK of single ascending intravenous doses of TAK-954.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
Enrollment StartMar 2019
First PostedMar 2019
Primary CompletionMay 2019
TodayJul 2026
First PostedMar 12, 2019
Enrollment StartMar 8, 2019
Primary CompletionMay 16, 2019
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 7.3 years ago
Interventions
TAK-954drug
TAK-954 infusion administered intravenously.
TAK-954 Placebodrug
TAK-954 placebo-matching infusion intravenous.